RecruitingPhase 3NCT06836128

The Combined Effect of N-Acetyl Cysteine and Metformin in Polycystic Ovary Syndrome Patients


Sponsor

Cairo University

Enrollment

102 participants

Start Date

Mar 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The study aims to evaluate the effects of combination of metformin with NAC in PCOS on biochemical and hormonal parameters.


Eligibility

Sex: FEMALEMin Age: 20 YearsMax Age: 45 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether combining two supplements — N-acetyl cysteine (NAC) and metformin — can help manage polycystic ovary syndrome (PCOS) more effectively than either alone. PCOS is a hormonal condition that can cause irregular periods, excess androgens, and fertility challenges. **You may be eligible if...** - You are a woman between 20 and 45 years old - You have been diagnosed with PCOS according to updated 2023 international guidelines - You are able to give informed consent **You may NOT be eligible if...** - You are allergic to metformin or NAC - You have taken medications affecting blood sugar (like insulin or sulfonylureas) or hormonal treatments in the past 2 months - You have high prolactin, diabetes, thyroid problems, or significant kidney or liver disease - You are pregnant or planning pregnancy during the study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGN-acetyl cysteine

N-Acetyl Cysteine (NAC) has antioxidant properties and is essential for the body's production of glutathione, and both glutathione and NAC are potent antioxidants.

DRUGMetfomin

metformin is commonly used for managing polycystic ovary syndrome (PCOS) due to its benefits in addressing several underlying features of the condition. While it is not officially approved by regulatory agencies like the FDA for PCOS, it is widely recognized and recommended in clinical practice guidelines as an off-label treatment for PCOS, particularly in women with insulin resistance and metabolic dysfunction.


Locations(1)

Kasr El-Ainy hospital

Cairo, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06836128


Related Trials